Skip to content

The Oncology Institute, Inc. TOI Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
12.5M0.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
15M0.0%
McKesson logo
McKessonMCK
Summit Therapeutics logo
Summit TherapeuticsSMMT
Exelixis logo
ExelixisEXEL
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s convertible preferred stock authorized shares?
The Oncology Institute, Inc. (TOI) reported convertible preferred stock authorized shares of 10M in Q1 2026.
How has The Oncology Institute, Inc.'s convertible preferred stock authorized shares changed year-over-year?
The Oncology Institute, Inc.'s convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 10M to 10M.
What is the long-term trend for The Oncology Institute, Inc.'s convertible preferred stock authorized shares?
Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s convertible preferred stock authorized shares has grown at a 0.0% compound annual growth rate (CAGR), from 10M to 10M.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.